What Is Refractory Angina and How Is It Treated?

Refractory angina is persistent chest pain caused by inadequate blood flow to the heart muscle that continues despite the best available medications and any revascularization procedures (stents or bypass surgery) that can reasonably be performed. By formal definition, the condition must last at least six months and require documented evidence that the heart is genuinely starved of oxygen, not just that the patient reports pain. Estimates suggest that between 600,000 and 1.8 million people in the United States live with refractory angina, and the number is growing as more patients survive heart disease into older age. The treatment landscape, though, is wider than most patients realize, extending well beyond pills and procedures into devices, nerve-based therapies, rehabilitation programs, and experimental cell treatments.

What Makes Angina “Refractory”

Angina becomes refractory when a patient has gone through the standard playbook and nothing has brought adequate relief. That playbook includes maximally tolerated doses of anti-ischemic drugs (beta-blockers, calcium channel blockers, long-acting nitrates) and any coronary revascularization that is technically possible, whether by stent or bypass grafting. A substantial share of patients with stable coronary artery disease still experience disabling symptoms after all of this and are sometimes labeled “no-option” patients.

1PubMed. Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies

A 2025 European Heart Journal consensus refined the definition to require that doctors actually demonstrate ischemia through testing of the coronary arteries, the tiny microvessels of the heart, and the potential for coronary vasospasm, rather than simply accepting that standard stress tests look bad. The rationale is straightforward: if a treatable mechanism has been missed, the angina is not truly refractory, it is just inadequately diagnosed.

2European Heart Journal. Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes – Section: Re-definition of refractory angina

How Many People Are Affected

Refractory angina is not rare, though precise numbers depend on how strictly you define it. Data from one large catheterization registry found that roughly 2,500 out of about 77,000 patients who underwent heart catheterization met the criteria, which aligns with the commonly cited estimate that up to 10 to 15 percent of patients undergoing catheterization fit the clinical description.

3Nature Reviews Cardiology. Treatment of refractory angina in patients not suitable for revascularization4PubMed Central. Predictors of long-term clinical endpoints in patients with refractory angina

In Europe, an estimated 30,000 to 50,000 new cases arise each year. In the United States, roughly 75,000 new cases are diagnosed annually, with between 600,000 and 1.8 million patients living with the condition at any given time. As survival from coronary artery disease improves and the population ages, these numbers are expected to climb, particularly because 7 to 14 percent of patients who undergo angiography have coronary anatomy that simply cannot be fixed with stents or surgery.

5European Heart Journal. Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes

Why the Pain Persists

The traditional picture of angina centers on a blockage in a major coronary artery that starves a section of heart muscle. In refractory angina, the causes are often more layered. A patient may have had bypass surgery years ago, but the grafts have narrowed. Or the large arteries are open, yet the tiny microvessels feeding the heart muscle are dysfunctional, a condition increasingly recognized in patients who have no obvious blockage at all. Coronary vasospasm, where an artery temporarily clenches shut, can also coexist with plaque-related disease. Myocardial bridging, where a segment of artery dips into the heart muscle and gets squeezed with each heartbeat, adds yet another layer.

These mechanisms can overlap. A patient may have partially blocked arteries plus microvascular dysfunction plus intermittent spasm, each contributing independently to ischemia. The updated European definition stresses that treatment-resistant angina sometimes simply reflects a failure to look for and diagnose these additional mechanisms, which means a thorough workup that tests coronary flow reserve and provokes vasospasm can sometimes reveal a treatable cause in patients previously told nothing more can be done.

6European Heart Journal. Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischaemic syndromes – Section: Mechanisms of myocardial ischaemia in patients with refractory angina

Medications Beyond the Usual Lineup

When standard drugs are not enough, second-line medications come into play. Ranolazine works differently from traditional anti-anginal drugs; rather than widening arteries or slowing the heart, it acts on ion channels in heart muscle cells to reduce the oxygen demand during each contraction. Ivabradine takes a separate approach by slowing the heart rate through a specific channel in the sinus node, without affecting blood pressure the way beta-blockers do.

Head-to-head data are limited, but a trial comparing the two in patients with chronic ischemic heart disease who still had symptoms found that both improved angina scores substantially over eight weeks, with ranolazine showing a somewhat larger improvement and a more favorable safety profile in that particular study.

7Journal of Ayub Medical College Abbottabad. COMPARISON OF EFFICACY AND SAFETY OF RANOLAZINE AND IVABRADINE IN CHRONIC ISCHEMIC HEART DISEASE PATIENTS

In practice, which drug gets tried first often depends on the patient’s heart rate, blood pressure, and tolerance of side effects rather than on a clear evidence hierarchy.

Enhanced External Counterpulsation

Enhanced external counterpulsation, or EECP, is a noninvasive treatment that resembles a mechanical workout for the circulatory system. Inflatable cuffs are wrapped around the patient’s calves, thighs, and buttocks. During each heartbeat’s relaxation phase, the cuffs squeeze in sequence from legs upward, pushing blood back toward the heart and increasing the pressure available to fill the coronary arteries. At the start of the next heartbeat, the cuffs rapidly deflate, reducing the resistance the heart has to pump against.

8PubMed Central. Enhanced external counterpulsation for refractory angina pectoris

A typical course runs 35 one-hour sessions over seven weeks. The treatment seems to work through several overlapping mechanisms: improving the function of the blood vessel lining, promoting the growth of collateral blood vessels, and triggering physical-training-like adaptations in the peripheral circulation.

9PubMed. Treatment options for refractory angina pectoris: enhanced external counterpulsation therapy

In one controlled trial, patients who received EECP showed a meaningful improvement in endothelial function, cut their daily nitrate tablet use by more than four tablets on average, and dropped from the most severe angina class to a milder one, while the control group saw no change on any of those measures.

10PubMed. External counterpulsation therapy improves endothelial function in patients with refractory angina pectoris

The Coronary Sinus Reducer

One of the more unusual devices in the refractory angina toolkit is the coronary sinus reducer, a small mesh implant placed into the coronary sinus, the main vein draining blood away from the heart. By partially narrowing that vein, the device raises pressure in the heart’s venous system, which is thought to redistribute blood flow toward the ischemic areas that need it most.

The first major randomized trial (COSIRA) tested the device against a sham procedure. At six months, about 71 percent of patients who received the reducer improved by at least one angina class, compared with 42 percent who got the sham procedure. About a third of reducer patients improved by two or more classes versus 15 percent of controls. Quality of life scores also favored the device.

11PubMed Central. Efficacy of a device to narrow the coronary sinus in refractory angina

The larger REDUCER-I registry, following 228 patients in routine clinical practice, confirmed durability: at two years, 82 percent of patients maintained at least a one-class improvement, and the proportion in the most severe angina categories dropped from 70 percent to 15 percent.

12PubMed Central. Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)

However, a more recent placebo-controlled trial (ORBITA-COSMIC) found that while patients with the device reported fewer daily angina episodes over six months, the reducer did not actually improve blood flow to the ischemic areas of the heart on stress imaging. The symptom benefit developed slowly, appearing around day 70 and growing through the rest of follow-up, which raises the question of how much of the improvement comes from physiology versus placebo response or gradual adaptation.

13The Lancet. Coronary sinus reducer in patients with refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial

This tension between symptomatic benefit and lack of measurable perfusion change has made the reducer a subject of genuine debate among cardiologists.

Spinal Cord Stimulation and Nerve Blocks

Spinal cord stimulation, or SCS, involves implanting a small electrode near the upper thoracic spinal cord. Low-level electrical pulses delivered through the electrode can reduce angina pain and appear to do more than just mask discomfort. Research suggests that the stimulation dials down sympathetic nerve activity, activates inhibitory circuits in the spinal cord that dampen pain signaling, and may improve blood flow at the microvascular level.

14PubMed Central. Spinal Cord Stimulation for Refractory Angina Pectoris

A related but less invasive approach is the stellate ganglion block, an injection of local anesthetic into a cluster of sympathetic nerves in the neck. By temporarily interrupting the sympathetic signals that can provoke coronary spasm and increase the heart’s oxygen demand, the block has provided meaningful relief in individual cases of end-stage coronary disease where repeated bypass operations, angioplasties, and laser therapy had already been tried.

15PubMed. Long-term benefits of stellate ganglion block in severe chronic refractory angina

The evidence base for stellate ganglion block remains limited mostly to case reports and small series, so it is generally reserved for patients who have exhausted other options or who need a bridge to longer-term neurostimulation.

16PubMed Central. Usefulness of stellate ganglion block for refractory angina pectoris

Shockwave Therapy

Extracorporeal shockwave myocardial revascularization, or ESMR, applies low-energy acoustic waves through the chest wall, targeted at ischemic areas of the heart identified by imaging. The rationale is that these mechanical pulses stimulate new blood vessel growth in the treated regions. Studies have found that ESMR increases markers of angiogenesis (the biological process of forming new blood vessels) and decreases markers of inflammation, with the greatest benefits appearing in patients whose follow-up imaging confirmed actual improvement in blood flow to the affected areas.

17PubMed. Effectiveness and Safety of Extracorporeal Shockwave Myocardial Revascularization in Patients With Refractory Angina Pectoris and Heart Failure18PubMed Central. The beneficial effect of extracorporeal shockwave myocardial revascularization in patients with refractory angina

ESMR is noninvasive, painless, and typically delivered in a series of sessions, making it attractive for frail patients who cannot tolerate more aggressive interventions. The evidence remains relatively early-stage, though, and it has not yet been tested in large randomized trials with sham controls, which makes it hard to separate the physiological benefit from a placebo effect.

Cell-Based Therapy

One of the more experimental approaches involves harvesting a patient’s own stem cells, specifically a type called CD34+ cells, mobilizing them from the bone marrow with growth factors, then injecting them directly into the ischemic heart muscle. In a phase II trial, 167 patients with refractory angina received either a low dose, a high dose, or placebo. Patients in the low-dose group experienced about six to seven angina episodes per week at six and twelve months, compared with about eleven per week in the placebo group. Exercise tolerance also improved significantly at both time points in the low-dose group.

19PubMed Central. Intramyocardial, autologous CD34+ cell therapy for refractory angina

A pooled analysis of cell therapy trials in refractory angina found that treated patients had substantially lower odds of major adverse cardiac events and of death compared with patients on standard medical therapy alone.

20PubMed. The Impact of Cell Therapy on Cardiovascular Outcomes in Patients With Refractory Angina

These are encouraging signals, but the technique remains investigational. It requires specialized facilities, the mobilization process takes days, and questions about the ideal cell dose, injection strategy, and long-term durability remain open.

Laser Revascularization and Its Cautionary Lesson

Transmyocardial laser revascularization, or TMLR, once generated considerable excitement. The idea was to use a laser to drill tiny channels through the heart wall, theoretically creating new pathways for blood to reach starved tissue. Early uncontrolled studies reported dramatic symptom improvements, which fueled rapid adoption.

Randomized trials told a more sobering story. One found that while a quarter of laser patients did improve by two or more angina classes (versus 4 percent of controls), the improvements in objective measures like exercise time and walking distance were neither statistically significant nor clinically important. Meanwhile, perioperative mortality was 5 percent, and overall survival at one year was worse in the laser group than in the group treated with medications alone, though not significantly so. The trial’s authors concluded that adoption of TMLR could not be advocated.

21The Lancet. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial

A percutaneous (catheter-based) version showed some benefit in angina symptoms and quality of life, but had no impact on mortality and left many questions about the appropriate dose and mechanism unanswered.

22PubMed Central. Effectiveness of percutaneous laser revascularization therapy for refractory angina

Laser revascularization illustrates an important pattern in refractory angina treatment: subjective symptom relief can be dramatic even when objective heart function barely changes, which makes placebo-controlled trials absolutely essential before concluding that a therapy works.

The Psychological Toll and How Multidisciplinary Programs Help

Refractory angina does not just limit physical activity. It exacts a heavy psychological toll. Patients frequently experience anxiety, depression, and a persistent fear that each episode of chest pain signals a heart attack. This distress feeds into a cycle where anxiety amplifies the perception of pain, which triggers more anxiety, which leads to more emergency visits and hospitalizations. Patients use healthcare services at rates far out of proportion to their mortality risk.

23PubMed Central. Management of Refractory Angina Pectoris24Journal of Cardiovascular Nursing. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris

Structured programs that combine medical management with psychological support, pain education, and physical rehabilitation have shown striking results. One study of 271 refractory angina patients enrolled in a cognitive-behavioral chronic disease management program found that total hospital admissions dropped from about 2.4 per patient per year to 1.8, hospital bed days fell from about 15.5 to 10.3, and myocardial infarction rates plummeted from 14 percent to about 2 percent in the year after enrollment.

25PubMed. A brief cognitive-behavioral intervention reduces hospital admissions in refractory angina patients

A separate multidisciplinary program showed that clinical anxiety levels dropped significantly, from 55 percent of patients at baseline to 40 percent at one year, alongside meaningful improvements in angina frequency, treatment satisfaction, and overall quality of life.

26PubMed. Health related quality of life of patients with refractory angina before and one year after enrolment onto a refractory angina program

Even cardiac rehabilitation, which patients with refractory angina are often steered away from out of fear it will worsen their symptoms, has been shown in a randomized pilot trial to improve physical capacity and reduce health-related anxiety without increasing angina frequency or severity.

27PubMed. Cardiac rehabilitation to improve physical functioning in refractory angina: a pilot study

What the Prognosis Actually Looks Like

One of the most important and counterintuitive things about refractory angina is that the prognosis is better than many patients and even some doctors assume. The label “refractory” sounds terminal, but mortality data tell a different story. A study following over 1,200 refractory angina patients for a median of about five years reported one-year mortality of roughly 4 percent, with nine-year mortality around 28 percent. Those numbers are higher than for stable angina in general but substantially lower than after a heart attack.

28PubMed. Long-term survival in patients with refractory angina29PubMed. Refractory angina pectoris carries a favourable prognosis: a three-year follow-up of 150 patients

The factors that predict worse outcomes are familiar ones in cardiology: older age, diabetes, more severe angina, chronic kidney disease, and reduced heart function. What this means in practical terms is that the main burden of refractory angina is not early death but rather years of impaired quality of life, which makes investments in symptom-control therapies and psychological support all the more important.

28PubMed. Long-term survival in patients with refractory angina

Healthcare Costs and the Case for the Reducer

The disproportionate use of healthcare services by refractory angina patients carries real financial consequences. Frequent emergency visits, repeat hospitalizations, and recurring coronary angiograms add up rapidly. A multicenter cost-effectiveness analysis of the coronary sinus reducer found that after implantation, patients in Belgium, the Netherlands, and Italy had significantly fewer angina-driven hospitalizations, outpatient visits, coronary angiograms, and percutaneous interventions per year, translating directly into reduced costs per patient per year.

30PubMed. Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients

The same economic argument applies to cognitive-behavioral programs and structured rehabilitation. When a brief outpatient program can cut hospital admissions by a quarter and halve bed-day occupancy, the savings can be large for healthcare systems that are absorbing the cost of repeat admissions for a growing population of patients who will not die from their disease but will keep returning to the emergency room without adequate support.

How Sex and Gender Shape the Picture

Refractory angina does not look the same in everyone. Women more often present with non-obstructive coronary artery disease and with ischemic mechanisms like coronary microvascular dysfunction and epicardial or microvascular spasm, rather than the large-vessel blockages that dominate in men.

31PubMed Central. Bridging the Gender Gap in Cardiovascular Medicine: Addressing Drug Intolerances and Personalized Care for Women with Angina/Ischemia with Non-Obstructive Coronary Artery Disease

This matters because many of the treatments discussed above were developed and tested primarily in patients with obstructive disease, who are disproportionately male. A woman whose angina stems from microvascular dysfunction may not respond to a therapy designed to redirect blood around a blocked artery, and she may need a different diagnostic workup and a different treatment plan entirely. The updated definition of refractory angina, with its emphasis on testing the coronary microcirculation and provoking spasm, is partly a response to growing recognition that the older, blockage-focused framework missed the mechanisms driving symptoms in many women. Comprehensive coronary function testing is increasingly seen as essential for any patient, but especially for women, before the label “refractory” is applied.